A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System

Yimin Zhang; Liang Yu; LingLing Tang; Mengfei Zhu; Yanqi Jin; Zhouhan Wang; Lanjuan Li

doi:10.1016/j.eng.2020.03.006

PDF(621 KB)

Engineering ›› 2021, Vol. 7 ›› Issue (1) : 11-13. DOI: 10.1016/j.eng.2020.03.006

Views & Comments

A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Yimin Zhang, Liang Yu, LingLing Tang, Mengfei Zhu, Yanqi Jin, Zhouhan Wang, Lanjuan Li. A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System. Engineering, 2021, 7(1): 11‒13 https://doi.org/10.1016/j.eng.2020.03.006

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. Lancet Respir Med 2020; 8(5):475–81.

[2]	Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet 2020;395 (10223):497–506.

[3]

National Health Commission of the People’s Republic of China. March 10: daily briefing on novel coronavirus cases in China [Internet]. Beijing: National Health Commission of the People’s Republic of China 2020 [updated 2020 Mar 10; cited 2020 Mar 12]. Available from: http://en.nhc.gov.cn/2020-03/10/ c_77552.htm.

[4]	Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.

[5]	De Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006;12(10):1203–7.

[6]	Guo J, Huang F, Liu J, Chen Y, Wang W, Cao B, et al. The serum profile of hypercytokinemia factors identified in H7N9-infected patients can predict fatal outcomes. Sci Rep 2015;5:10942.

[7]	Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004;136(1):95–103.

[8]	Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine 2018;104:8–13.

[9]	Hui DSC, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am 2019;33(4):869–89.

[10]	Azhar EI, Hui DSC, Memish ZA, Drosten C, Zumla A. The Middle East respiratory syndrome (MERS). Infect Dis Clin North Am 2019;33(4):891–905.

[11]	Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet 2020;395 (10224):E35–6.

[12]	Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–13.

[13]	Kui L, Fang Y, Deng Y, Liu W, Wang M, Ma J, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J 2020;133(9):1025–31.

[14]	Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006;3(9):e343.

[15]	Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 2018;197(6):757–67.

[16]	Salto-Tellez M, Tan E, Lim B. ARDS in SARS: cytokine mediators and treatment implications. Cytokine 2005;29(2):92–4.

[17]	Hughes RD. Review of methods to remove protein-bound substances in liver failure. Int J Artif Organs 2002;25(10):911–7.

[18]	Liu X, Zhang Y, Xu X, Du W, Su K, Zhu C, et al. Evaluation of plasma exchange and continuous veno-venous hemofiltration for the treatment of severe avian influenza A (H7N9): a cohort study. Ther Apheresis Dial 2015;19(2):178–84.

[19]	Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan JH, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013;368 (24):2277–85.

[20]	Sadeghi M, Daniel V, Wang H, Zeier M, Schemmer P, Mehrabi A, et al. Plasmapheresis adjusts inflammatory responses in potential kidney transplant recipients. Transplantation 2013;95(8):1021–9.

[21]	Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. Management of corona virus disease-19(COVID-19): the Zhejiang experience. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020;49(2):147–57. Chinese.

[22]	National Clinical Research Center for Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Disease. Expert consensus on the application of artificial-liver blood-purification system in the treatment of severe COVID-19. Chin J Clin Infect Dis. Epub 2020 Feb. Chinese.

[23]

National Health Commission of the People’s Republic of China, National Administration of Traditional Chinese Medcine. Guideline for diagnosis and treatment of COVID-19 (7th version) [Internet]. [updated 2020 Mar 3; cited 2020 Mar 12]. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202003/ 46c9294a7dfe4cef80dc7f5912eb1989/files/ ce3e6945832a438eaae415350a8ce964.pdf. Chinese.

[24]	Zhou N, Li J, Zhang Y, Lu J, Chen E, Du W, et al. Efficacy of coupled low-volume plasma exchange with plasma filtration adsorption in treating pigs with acute liver failure: a randomised study. J Hepatol 2015;63(2):378–87.